Drug Trial Radar · NCT01911494
Community Level Interventions for Pre-eclampsia
Last checked: Nov 19, 2026Latest source record: Jun 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87,500
Planned (sponsor's estimate)
Start
Sep 2013
Primary completion
May 2018
Study completion Jun 2018
Sponsor
- Lead sponsor
- University of British ColumbiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation; Olabisi Onabanjo University; Centro de Investigacao em Saude de Manhica; Aga Khan University; Jawaharlal Nehru Medical College
- First posted
- Jul 30, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- Female only, from 15 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This project is being undertaken to test the hypothesis that implementing a community based package of care for women with hypertensive disorders of pregnancy will result in overall improvement in maternal and neonatal outcomes. This is based on the premise that there are three main modifiable reasons why women (and their fetuses/newborns) die due to pregnancy complications: 1) delays by the woman herself in recognizing the seriousness of her condition; 2) delays in her being assessed and then transported to a center capable of providing effective and life-saving interventions; and 3) delays in the health facility in providing those interventions. The treatments for pre-eclampsia that are poorly accessed in LMIC are 1) magnesium sulfate (MgSO4) for prevention and treatment of the grand mal seizures of eclampsia; 2) oral antihypertensive medication to lower maternal BP to reduce the risk of stroke. The CLIP pilot and definitive cRCT will investigate whether the community level intervention including implementation of the CLIP package (oral antihypertensive therapy when indicated, intramuscular (i.m.) MgSO4 when indicated; and appropriate referral to an CEmOC facility when indicated) of care will reduce the incidence of all-cause maternal morbidity and mortality.
Conditions
- Pre-eclampsia
- Hypertension, Pregnancy Induced
Interventions
Community EngagementBehavioral
The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
PIERS on the Move mHealth decision aidDevice
This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (\>160mmHg systolic) or proteinuria (\>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
Magnesium SulfateDrug
Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
MethyldopaDrug
Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maternal or Perinatal death or morbidityTime frame: within 42 days of pregnancy
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Jawaharlal Nehru Medical College, Karnataka Lingayat Education University
Belagavi, Karnataka, India
Centro de Investigacaoem Saude de Manhica (CISM)
Maputo, Mozambique
Centre for Research in Reproductive Health, Olabisi Onabanjo University
Sagamu, Ogun State, Nigeria
Aga Khan University
Karachi, Sindh, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.